Novartis’ immunology drug Cosentyx (secukinumab) notched its sixth indication, gaining U.S. approval as a hidradenitis suppurativa (HS) therapy, the drugmaker said this week. The regulatory OK makes ...
The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...
Psoriasis is not simply a cosmetic problem, but a persistent, chronic (long-lasting), and sometimes distressing disease, which can affect even the smallest aspects of people`s lives on a daily ...
cosentyx article Cosentyx is the first and only fully-human interleukin-17A (IL-17A) antagonist. In the SCALP study, patients with moderate to severe psoriasis lesions of the scalp (n=102) were ...
Data from the Phase III ECLIPSE head-to-head trial for Johnson & Johnson’s (J&J) interleukin 23 (IL-23) inhibitor Tremfya (guselkumab) in psoriasis patients showed that Tremfya was more effective than ...
Cosentyx may soon share the hidradenitis suppurativa (HS) field with another inflammatory biologic—but, for now, the Novartis drug has a head start. That’s good news for the Swiss Pharma, given that ...
Please provide your email address to receive an email when new articles are posted on . This approval makes Cosentyx the first interleukin-17A inhibitor and second biologic approved for hidradenitis ...
Beating AbbVie’s TNF blocker Humira in a head-to-head trial has become a rite of passage for new interleukin-targeting drugs in the immunology market, but Novartis’ Cosentyx has just fallen short on ...
Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in November. The drug’s manufacturer, Novartis, said Sept.
The FDA has approved Cosentyx® (secukinumab; Novartis) for the treatment of adults with active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. The Food and ...
Novartis’ psoriasis drug, Cosentyx (secukinumab) received a boost after data showed it is better at clearing skin than Johnson & Johnson’s rival Stelara. Cosentyx is one of several newer drugs that ...
Cosentyx (secukinumab) may be safe to use while pregnant or breastfeeding. Before starting treatment, you and your doctor can discuss the risks and benefits of Cosentyx treatment during pregnancy or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results